|
|
|
23.04.26 - 13:06
|
Ocugen to Present at April 2026 Investor and Industry Conferences (GlobeNewswire EN)
|
|
|
MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at Oppenheimer's 3rd Annual Innovation on the Island Biotech Summit from April 27-29, 2026 in Rio Grande, Puerto Rico; and Abhi Gupta, MBA, Executive Vice President, Commercial and Business Development at Ocugen will present at the 2026 Cell & Gene Meeting on the Mediterranean being held April 28-30, 2026 in Rome, Italy....
|
|
|
|
|
|
|
|
|
10.04.26 - 15:57
|
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells (PR Newswire)
|
|
|
AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disease Issued on behalf of Avaí Bio, Inc. Companies mentioned in this article: Avaí Bio, Inc. (OTCQB: AVAI), Lineage Cell Therapeutics, Inc. (NYSE American: LCTX), Ocugen, Inc. (NASDAQ: OCGN),......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.03.26 - 12:03
|
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy (GlobeNewswire EN)
|
|
|
MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with key opinion leaders (KOLs) and Ocugen executive leadership to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy (GA), late-stage dry age-related macular degeneration (dAMD) at 8 a.m. EDT on Tuesday, March 24, 2026....
|
|
|
|
|
|
|
|
|
11.03.26 - 21:33
|
Why Is Ocugen Stock Soaring Today? (Benzinga)
|
|
|
Ocugen shares are surging Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated coverage with an Outperform rating and a $10 price target.
Importance Rank:
1
read more...
|
|
|
|
|
11.03.26 - 15:24
|
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline (24/7 Wall St.)
|
|
|
Oppenheimer initiated coverage of Ocugen (NASDAQ:OCGN) with an Outperform rating and a $10 price target on Wednesday, positioning the clinical-stage gene therapy company as an emerging leader in blinding ocular disorders. The call arrives just days after Ocugen completed enrollment in its Phase 3 retinitis pigmentosa trial and reported full-year 2025 financials that reflected both ... Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline
The post Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline appeared first on 24/7 Wall St.....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
